Three Australian Health Companies Report Progress in Quarterly Update
Published
A recent quarterly review by Kalkine looks at three health companies listed on the Australian Securities Exchange (ASX). The companies are Biome Australia (ASX: BIO), EMVision (ASX: EMV) and Artrya (ASX: AYA). The review describes how each business has moved forward over the past few months.
The clearest update concerns Biome Australia, a company that works with probiotics, which are products containing helpful bacteria. According to the report, manufacturing with Specialty Probiotics Australia is already under way. The company is aiming to sell Australian-made products from November 2026. The report also mentions a heads of agreement, which is a non-binding document that sets out the main terms of a future deal. The available summary does not give full details of this agreement.
The report also covers EMVision and Artrya. However, the short summary available does not provide specific details about their progress. Readers who want more information about these two companies will need to read the full Kalkine report.
In summary, the review shows that Biome Australia is moving ahead with local manufacturing plans, while the other two companies are also being tracked in the same health sector update. Because these companies are listed on the ASX, their progress may be of interest to investors and to people following Australia's health industry.
Sources: Kalkine
More Australia news
- Trellis Data unveils Agentaus 1 AI model in Australia
- Australia set to run out of Q fever vaccine this week
- Missing 17-year-old William found alive in Victoria bushland
- Australia to Create New AI Safety Regulator After OpenAI Incident
- Australia Moves to Tighten AI Safety Laws After Review of OpenAI Incident
- Qantas to Cut Nearly 1,000 Jobs as It Points to Artificial Intelligence
- Australia to Introduce Mandatory AI Reporting After OpenAI Hack
- Australia Plans New AI Safety Standards and a Watchdog to Enforce Them